BostonGene Announces Three Abstract Acceptances at ESMO Congress 2023

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2023. This highly influential oncology event brings together clinicians, researchers, patient advocates, journalists and healthcare industry representatives from around the world to exchange and debate translational cancer science, present potentially practice-changing data and stimulate multidisciplinary discussions to improve treatment options for our patients. The event will be held on October 20 - 24, 2023, in Madrid, Spain, at the IFEMA MADRID. BostonGene will also exhibit in Hall 5, booth 550.

BostonGene session details are below:

Abstract: 1215P
Title: Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Date: Sunday, October 22
Presenter: Chris Davitt, PhD, BostonGene

This study compared the utility of cell-free DNA (cfDNA) liquid biopsy with tumor-based next-generation sequencing approaches, revealing a 66.2% and 31.4% increase in the detection of single nucleotide variants and insertions and deletions, respectively, in clinically actionable gene panels using cfDNA.

Abstract: 1963P
Title: Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Date: Monday, October 23
Presenter: Alexander Bagaev, PhD, BostonGene

Whole exome and whole transcriptome sequencing of chordoma patients identified distinct tumor microenvironment (TME) subtypes. In total, 89% of patients had immune-enriched (IE and IE/F) TMEs, highlighting potential avenues for targeted therapies, particularly immune checkpoint inhibitors, in the management of advanced chordomas.

Abstract: 1982P
Title: Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi Sarcoma (KS)
Date: Monday, October 23
Presenter: Krystle Nomie, PhD, BostonGene

Transcriptomic analysis of HIV-positive and HIV-negative Kaposi Sarcoma (KS) patients revealed unique tumor microenvironment (TME) characteristics related to treatment response, suggesting potential avenues for novel therapeutic strategies in KS and emphasizing the importance of understanding the interplay between immune status and the TME.

To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at [e-mail].

For more information, please visit the ESMO Congress 2023 website.

About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.